Home
About
Overview
Sharing Data
ORCID
Help
History (26)
Progressive Neurologic Changes in a Patient With Metastatic Non-Small-Cell Lung Cancer: Cancer Effects or a Secondary Diagnosis?
SOX9: The master regulator of cell fate in breast cancer.
Transactivation of the receptor-tyrosine kinase ephrin receptor A2 is required for the low molecular weight hyaluronan-mediated angiogenesis that is implicated in tumor progression.
Maintenance therapy in NSCLC: why? To whom? Which agent?
Tumor Heterogeneity and Therapeutic Resistance.
See All 26 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Tumor Heterogeneity and Therapeutic Resistance.
Tumor Heterogeneity and Therapeutic Resistance. Am Soc Clin Oncol Educ Book. 2016; 35:e585-93.
View in:
PubMed
subject areas
Genome, Human
High-Throughput Nucleotide Sequencing
Humans
Molecular Targeted Therapy
Neoplasms
authors with profiles
Ravi Salgia